Susana Vives

Universitat Autònoma de Barcelona — Spain

Medicine · Health Sciences

22h-index2.1kcitations190works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(114), Acute Lymphoblastic Leukemia research(50), Chronic Myeloid Leukemia Treatments(38), Myeloproliferative Neoplasms: Diagnosis and Treatment(31), Hematopoietic Stem Cell Transplantation(22)

Publications190 total

Erratum: Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study
Journal of Clinical Oncology·2025
Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory <scp> <i>FLT3</i> </scp> ‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 Patients
American Journal of Hematology·2025Open Access
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AML
Future Oncology·2025· 1 citedOpen Access
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed <i>IDH1</i> mutant acute myeloid leukemia
Future Oncology·2025· 1 citedOpen Access
A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study
Haematologica·2025Open Access
Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers
Blood·2025Open Access
Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial
Blood·2025Open Access
Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study
Blood·2025Open Access
Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights
Blood·2025
Prognostic implications of commutational patterns in NPM1-mutated AML receiving intensive treatment. cetlam group study
Blood·2025
Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia
Blood·2025· 2 cited
Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy
Blood·2025Open Access
Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry
Blood·2025
Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients
Blood·2025Open Access
CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study
Blood·2025Open Access
Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry
Blood·2025
Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial
Blood Neoplasia·2025Open Access
Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study
Journal of Clinical Oncology·2025Open Access
Management guide for treatment with venetoclax and azacitidine in patients with acute myeloid leukemia ineligible for intensive chemotherapy
Revista Sangre (ENG)·2025Open Access
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry
Leukemia·2025Open Access
page 1 of 10Next →

Frequent Co-authors

Pau Montesinos(30), Mar Tormo(27), Josep‐María Ribera(20), Juan Bergua(19), Cristina Gil(17), Jordi Esteve(15), Mireia Morgades(15), Evarist Feliú(14), Josefina Serrano(13), Miguel Á. Sanz(13), Santiago Mercadal(13), Ferran Vall‐Llovera(12), Joaquín Martínez‐López(12), Josep Nomdedéu(11), David Martínez‐Cuadrón(11), Olga Salamero(11), Rosa Coll(10), Eulàlia Genescà(10), Pere Barba(10), Jordi Ribera(10)